Remdesivir Recruiting Phase 3 Trials for Novel Coronavirus Infectious Disease (COVID-19) / COVID-19 Pneumonia Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04252664Mild/Moderate 2019-nCoV Remdesivir RCT
NCT04401579Adaptive COVID-19 Treatment Trial 2 (ACTT-II)
NCT04409262A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
NCT04280705Adaptive COVID-19 Treatment Trial (ACTT)